Jeffrey M. Jacobson

9.0k total citations
133 papers, 5.0k citations indexed

About

Jeffrey M. Jacobson is a scholar working on Virology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Jeffrey M. Jacobson has authored 133 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Virology, 68 papers in Infectious Diseases and 46 papers in Epidemiology. Recurrent topics in Jeffrey M. Jacobson's work include HIV Research and Treatment (78 papers), HIV/AIDS Research and Interventions (40 papers) and HIV/AIDS drug development and treatment (39 papers). Jeffrey M. Jacobson is often cited by papers focused on HIV Research and Treatment (78 papers), HIV/AIDS Research and Interventions (40 papers) and HIV/AIDS drug development and treatment (39 papers). Jeffrey M. Jacobson collaborates with scholars based in United States, Canada and United Kingdom. Jeffrey M. Jacobson's co-authors include Michael M. Lederman, John Spritzler, Ronald J. Bosch, William C. Olson, Daniel R. Kuritzkes, Miriam Chernoff, William G. Powderly, Ellen S. Chan, Rajesh T. Gandhi and Richard Hafner and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nature Medicine.

In The Last Decade

Jeffrey M. Jacobson

127 papers receiving 4.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey M. Jacobson United States	38	2.5k	2.1k	1.4k	1.3k	828	133	5.0k
Maria Carla Re Italy	35	1.9k 0.8×	1.5k 0.7×	1.2k 0.8×	1.1k 0.9×	894 1.1×	258	4.6k
Yvonne J. Bryson United States	41	2.7k 1.1×	2.8k 1.3×	2.8k 2.0×	1.5k 1.2×	514 0.6×	143	6.3k
William Borkowsky United States	39	3.8k 1.5×	2.8k 1.3×	2.3k 1.7×	2.6k 2.0×	621 0.8×	155	6.7k
Sheila M. Keating United States	36	1.8k 0.7×	1.8k 0.8×	1.3k 0.9×	1.4k 1.1×	878 1.1×	127	4.6k
David M. Asmuth United States	29	1.5k 0.6×	1.0k 0.5×	924 0.7×	907 0.7×	468 0.6×	77	3.1k
Gerrit Jan Weverling Netherlands	40	1.6k 0.6×	2.5k 1.2×	1.6k 1.1×	559 0.4×	640 0.8×	88	5.0k
Frank de Wolf Netherlands	33	3.1k 1.3×	2.5k 1.2×	1.1k 0.8×	1.1k 0.9×	421 0.5×	67	4.4k
Paul R. Skolnik United States	35	1.8k 0.7×	1.9k 0.9×	1.5k 1.0×	997 0.8×	256 0.3×	77	4.2k
Luis J. Montaner United States	46	3.1k 1.2×	2.1k 1.0×	1.3k 0.9×	3.7k 2.9×	1.1k 1.3×	190	6.9k
Jonathan B. Angel Canada	41	1.7k 0.7×	1.9k 0.9×	1.4k 1.0×	1.8k 1.4×	708 0.9×	177	5.5k

Countries citing papers authored by Jeffrey M. Jacobson

Since Specialization

Citations

This map shows the geographic impact of Jeffrey M. Jacobson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey M. Jacobson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey M. Jacobson more than expected).

Fields of papers citing papers by Jeffrey M. Jacobson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey M. Jacobson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey M. Jacobson. The network helps show where Jeffrey M. Jacobson may publish in the future.

Co-authorship network of co-authors of Jeffrey M. Jacobson

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey M. Jacobson. A scholar is included among the top collaborators of Jeffrey M. Jacobson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey M. Jacobson. Jeffrey M. Jacobson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Salata, Robert A., et al.. (2025). Impact of hepatic steatosis on mortality, hepatocellular carcinoma, end-stage liver disease and HBsAg seroclearance in chronic hepatitis B: a United States cohort study. PubMed. 16. 1566925–1566925.

Yendewa, George A., et al.. (2024). Risk Stratification of Advanced Fibrosis in Patients With Human Immunodeficiency Virus and Hepatic Steatosis Using the Fibrosis-4, Nonalcoholic Fatty Liver Disease Fibrosis, and BARD Scores. Open Forum Infectious Diseases. 11(2). ofae014–ofae014. 4 indexed citations

Qing, Yulan, Ricky Chan, Pingfu Fu, et al.. (2023). Impact of age, antiretroviral therapy, and cancer on epigenetic aging in people living with HIV. Cancer Medicine. 12(9). 11010–11019. 4 indexed citations

Spinelli, Matthew A., Jennifer Jain, Nadra E. Lisha, et al.. (2023). Viral Suppression Trajectories Destabilized After Coronavirus Disease 2019 Among US People With Human Immunodeficiency Virus: An Interrupted Time Series Analysis. Clinical Infectious Diseases. 78(4). 991–994. 2 indexed citations

Giron, Leila B., Clovis S. Palmer, Qin Liu, et al.. (2021). Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV. Nature Communications. 12(1). 3922–3922. 37 indexed citations

Presti, Rachel M., Brett Williams, Alan Landay, et al.. (2021). A Randomized, Placebo-Controlled Trial Assessing the Effect of VISBIOME ES Probiotic in People With HIV on Antiretroviral Therapy. Open Forum Infectious Diseases. 8(12). ofab550–ofab550. 12 indexed citations

Andrade, Viviane M., Carla Mavian, Dunja Z. Babič, et al.. (2020). A minor population of macrophage-tropic HIV-1 variants is identified in recrudescing viremia following analytic treatment interruption. Proceedings of the National Academy of Sciences. 117(18). 9981–9990. 45 indexed citations

Yendewa, George A., Sulaiman Lakoh, Hannah Lawrence, et al.. (2020). Prevalence of hepatitis B surface antigen and serological markers of other endemic infections in HIV-infected children, adolescents and pregnant women in Sierra Leone: A cross-sectional study. International Journal of Infectious Diseases. 102. 45–52. 14 indexed citations

Jacobson, Jeffrey M., Julie K. Jadlowsky, Simon F. Lacey, et al.. (2020). Autologous CD4 T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals. Molecular Therapy. 29(2). 626–635. 5 indexed citations

10.

Williams, Brett, Stefan J. Green, Ronald J. Bosch, et al.. (2019). Four Weeks of Treatment With Rifaximin Fails to Significantly Alter Microbial Diversity in Rectal Samples of HIV-Infected Immune Non-Responders (ACTG A5286) Which May be Attributed to Rectal Swab Use. SHILAP Revista de lepidopterología. 4(2). 235–235. 8 indexed citations

11.

Papasavvas, Emmanouil, Livio Azzoni, Andrew V. Kossenkov, et al.. (2019). NK Response Correlates with HIV Decrease in Pegylated IFN-α2a–Treated Antiretroviral Therapy–Suppressed Subjects. The Journal of Immunology. 203(3). 705–717. 17 indexed citations

12.

Dampier, Will, Neil T. Sullivan, Joshua Chang Mell, et al.. (2018). Broad-Spectrum and Personalized Guide RNAs for CRISPR/Cas9 HIV-1 Therapeutics. AIDS Research and Human Retroviruses. 34(11). 950–960. 26 indexed citations

13.

Gandhi, Rajesh T., Lu Zheng, Ronald J. Bosch, et al.. (2010). The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial. PLoS Medicine. 7(8). e1000321–e1000321. 242 indexed citations

14.

Petrovas, Constantinos, Benjamin Chaon, David R. Ambrozak, et al.. (2009). Differential Association of Programmed Death-1 and CD57 with Ex Vivo Survival of CD8+ T Cells in HIV Infection. The Journal of Immunology. 183(2). 1120–1132. 91 indexed citations

15.

Jacobson, Jeffrey M., Daniel R. Kuritzkes, Eliot Godofsky, et al.. (2008). Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected Adults. Antimicrobial Agents and Chemotherapy. 53(2). 450–457. 125 indexed citations

16.

Parada, Jorge P., Maria Deloria Knoll, Joan S. Chmiel, et al.. (2004). HIV-Related Pneumonia Care in Older Patients Hospitalized in the Early HAART Era. AIDS Patient Care and STDs. 18(2). 99–107. 8 indexed citations

17.

Cohen, Mary Ann, et al.. (2003). Treatment of Interferon-Induced Psychosis in Patients With Comorbid Hepatitis C and HIV. Psychosomatics. 44(5). 417–420. 14 indexed citations

18.

Jacobson, Jeffrey M., Richard Hafner, Jack S. Remington, et al.. (2001). Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS. AIDS. 15(5). 583–589. 30 indexed citations

19.

Jacobson, Jeffrey M., John S. Greenspan, John Spritzler, et al.. (2001). Thalidomide in Low Intermittent Doses Does Not Prevent Recurrence of Human Immunodeficiency Virus–Associated Aphthous Ulcers. The Journal of Infectious Diseases. 183(2). 343–346. 17 indexed citations

20.

Luft, Benjamin J., Richard Hafner, Ann H. Korzun, et al.. (1993). Toxoplasmic Encephalitis in Patients with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine. 329(14). 995–1000. 293 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact